Docs 'excited' to learn more about new migraine drugs from Biohaven, Lilly and AbbVie: analyst

With numerous approvals over the last few years, the migraine field—both acute treatment and prevention—has been heating up. That was clear at this year’s American Headache Society (AHS) annual meeting, where despite the virtual format, doctors were “excited” to learn more about new options, SVB Leerink analysts wrote in a note to clients.